Related Experiment Videos

[MR contrast media for cardiovascular imaging]

G A Krombach1, C B Higgins, R W Günther

  • 1Department of Radiology, University of California, San Francisco, California, USA.

Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|July 9, 2002
PubMed

Insights

MR contrast media enhance MRI and MRA diagnostics for heart conditions. Emerging intravascular, necrosis-specific, and intracellular agents offer improved myocardial assessment and interventions.

Area of Science:

  • Cardiovascular Imaging
  • Magnetic Resonance Imaging (MRI)
  • Contrast Media

Context:

  • Current clinical MRI and MRA studies primarily use extracellular, non-specific contrast agents like Gd-DTPA.
  • These agents are crucial for differentiating myocardial viability, infarction types, and measuring perfusion.
  • Limitations exist in current contrast media applications for complex cardiovascular assessments.

Purpose:

  • To explore the feasibility and applications of novel MR contrast media in cardiovascular imaging.
  • To evaluate intravascular, necrosis-specific, intracellular, and endogenous contrast agents.
  • To expand diagnostic capabilities beyond current extracellular agents.

Summary:

  • Experimental and clinical studies demonstrate the potential of intravascular, necrosis-specific, intracellular, and endogenous contrast media for cardiovascular MRI and MRA.
  • Intravascular agents (e.g., MS-325) assess microvascular integrity and aid MR angiography.
  • Necrosis-specific agents (e.g., Gadophrin-2) size myocardial infarcts, while intracellular agents (e.g., Mn-DPDP) delineate viable myocardium.

Impact:

  • Novel contrast media promise enhanced diagnostic accuracy in cardiovascular imaging.
  • These agents facilitate detailed assessment of myocardial perfusion, integrity, and infarct extent.
  • Potential for improved MRI/MRA guided cardiovascular interventions and personalized treatment strategies.

Related Concept Videos